Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Articles published by Blade Therapeutics, Inc.

Blade Therapeutics Presents Analyses from Phase 1 and Preclinical Studies of Cudetaxestat at the European Respiratory Society International Congress 2022
From Blade Therapeutics, Inc.
Via Business Wire
Blade Therapeutics to Participate in “Drug Development in Pulmonary Medicine” Panel Discussion at 2022 BTIG Biotechnology Conference
From Blade Therapeutics, Inc.
Via Business Wire
Tickers BIOT
Blade Therapeutics Presents Preclinical Data Highlighting Differentiating Characteristics of Cudetaxestat at the American Thoracic Society 2022 International Conference
From Blade Therapeutics, Inc.
Via Business Wire
Tickers BIOT
Blade Therapeutics Presents Data from Phase 1 and Preclinical Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference
From Blade Therapeutics, Inc.
Via Business Wire
Tickers BIOT
Blade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data Package
From Blade Therapeutics, Inc.
Via Business Wire
Tickers BIOT
Blade Therapeutics to Present Data from Preclinical and Phase 1 Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference
From Blade Therapeutics, Inc.
Via Business Wire
Tickers BIOT
Blade Therapeutics Announces Successful Completion of Phase 1 Clinical Study that Evaluated Co-Administration of Cudetaxestat with Either of Two Approved Therapies for Idiopathic Pulmonary Fibrosis
From Blade Therapeutics, Inc.
Via Business Wire
Tickers BIOT
Blade Therapeutics Announces Positive Topline Data from Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis
From Blade Therapeutics, Inc.
Via Business Wire
Blade Therapeutics Appoints Bassem Elmankabadi, M.D., as Senior Vice President of Clinical Development
From Blade Therapeutics, Inc.
Via Business Wire
Blade Therapeutics Initiates Additional Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis
From Blade Therapeutics, Inc.
Via Business Wire
Blade Therapeutics Announces FDA Orphan Drug Designation Granted to Cudetaxestat for Treatment of Systemic Sclerosis
From Blade Therapeutics, Inc.
Via Business Wire
Blade Therapeutics Mourns the Passing of General Counsel and Secretary Alan C. Mendelson
From Blade Therapeutics, Inc.
Via Business Wire
Blade Therapeutics Announces Publication of Preclinical Evidence Supporting Neuroprotective Effects of Proprietary Calpain Inhibitor in a Rare Inherited Neurodegenerative Disease
From Blade Therapeutics, Inc.
Via Business Wire
Blade Therapeutics Announces Positive Data from Preclinical Drug-Drug Interaction Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis (IPF)
From Blade Therapeutics, Inc.
Via Business Wire
Blade Therapeutics Announces FDA Activation of IND Application to Investigate Cudetaxestat, a Non-Competitive Autotaxin Inhibitor, in Idiopathic Pulmonary Fibrosis (IPF)
From Blade Therapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.